GOLDMAN SACHS GROUP INC - 28 Sep 2023 Form 3 Insider Report for BIOLASE, INC (BIOLQ)

Role
10%+ Owner
Signature
/s/ Crystal Orgill
Issuer symbol
BIOLQ
Transactions as of
28 Sep 2023
Net transactions value
$0
Form type
3
Filing time
06 Oct 2023, 17:25:51 UTC
Previous filing
01 Sep 2023
Next filing
13 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BIOL Common Stock 144,501 28 Sep 2023 See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This statement is being filed by The Goldman Sachs Group, Inc. ("GS Group") and Goldman Sachs & Co. LLC ("Goldman Sachs" and together with GS Group, the "Reporting Persons"). Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. On September 28, 2023, the Reporting Persons experienced an increase in their beneficial ownership of Biolase, Inc. (the "Issuer") to above 10% of the outstanding Common Stock. On September 29, 2023, the Reporting Persons experienced a decrease in their beneficial ownership that reduced their beneficial ownership to below 10% of the Issuer's outstanding Common Stock due to a reduction in excess securities borrows.
F2 The Common Stock of the Issuer reported herein as indirectly purchased were beneficially owned directly by Goldman Sachs and indirectly by GS Group.